Tech Company Financing Transactions
Bridge Biotherapeutics Funding Round
On 6/20/2025, Bridge Biotherapeutics raised $183.3 million in funding from Parataxis Capital.
Transaction Overview
Company Name
Announced On
6/20/2025
Transaction Type
Venture Equity
Amount
$183,300,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
C's Tower, 58, Pangyo-ro 255 beon-gil, Bundang-gu 303
Seongnam-si, Gyeonggi-do, 13486
South Korea
Seongnam-si, Gyeonggi-do, 13486
South Korea
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Bridge Biotherapeutics is a publicly listed, clinical stage biotech company, founded in 2015 and headquartered in the Republic of Korea. We are highly committed to restoring and improving the lives of patients by developing novel compounds into innovative new drugs through rigorous global clinical development processes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Lee
Browse more venture capital transactions:
Prev: 6/20/2025: TerraPower venture capital transaction
Next: 6/20/2025: Ostrom venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs